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AbstrAct
Objective To ascertain whether different oral P2Y12 
inhibitors might affect rates of acute stent thrombosis and 
30-day outcomes after primary percutaneous coronary 
intervention (pPCI).
Methods The European Ambulance Acute Coronary 
Syndrome Angiography (EUROMAX) randomised trial 
compared prehospital bivalirudin with heparin with 
optional glycoprotein IIb/IIIa inhibitor treatment in patients 
with ST-segment elevation myocardial infarction triaged 
to pPCI. Choice of P2Y
12 inhibitor was at the investigator’s 
discretion. In a prespecified analysis, we compared event 
rates with clopidogrel and newer oral P2Y12 inhibitors 
(prasugrel, ticagrelor). Rates of the primary outcome 
(acute stent thrombosis) were examined as a function of 
the P2Y
12 inhibitor used for loading and 30-day outcomes 
(including major adverse cardiac events) as a function of 
the P2Y12 inhibitor used for maintenance therapy. Logistic 
regression was used to adjust for differences in baseline 
characteristics.
Results Prasugrel or ticagrelor was given as the 
loading P2Y
12 inhibitor in 49% of 2198 patients and as 
a maintenance therapy in 59%. No differences were 
observed in rates of acute stent thrombosis for clopidogrel 
versus newer P2Y
12 inhibitors (adjusted OR 0.50, 95% 
CI 0.13 to 1.85). After adjustment, no difference was 
observed in 30-day outcomes according to maintenance 
therapy except for protocol major (p=0.029) or minor 
(p=0.025) bleeding and Thrombolysis In Myocardial 
Infarction minor bleeding (p=0.002), which were less 
frequent in patients on clopidogrel. Consistent results were 
observed in the bivalirudin and heparin arms.
Conclusions The choice of prasugrel or ticagrelor over 
clopidogrel was not associated with differences in acute 
stent thrombosis or 30-day ischaemic outcomes after 
pPCI.
Trial registration number NCT01087723.
InTROduCTIOn
A rapid and powerful platelet inhibition 
appears key in patients with ST-segment eleva-
tion myocardial infarction (STEMI) referred 
for primary percutaneous coronary inter-
vention (pPCI). In pivotal trials,1 2 the use 
of prasugrel or ticagrelor versus clopidogrel 
was associated with a reduction in the rate of 
ischaemic events. While the overall rate of 
stent thrombosis was reduced with prasugrel 
or ticagrelor in the overall population1 2 as 
well as in the subgroup of patients with STEMI 
treated with pPCI,3 4 there was no difference 
in rates of acute stent thrombosis.5 6 Recent 
studies have provided a rationale for this 
observation, showing that the onset of anti-
platelet effect with P2Y12 inhibitors such as 
prasugrel and ticagrelor can be delayed in 
STEMI compared with that in stable patients 
or healthy volunteers.7–10 
The European Ambulance Acute Coro-
nary Syndrome Angiography (EUROMAX) 
trial11 compared prehospital bivalirudin with 
heparin (unfractionated heparin [UFH] or 
low-molecular-weight heparin) with/without 
glycoprotein IIb/IIIa inhibitor treatment 
and found a significant reduction in death or 
major bleeding with bivalirudin. EUROMAX 
Key questions
What is already known about this subject?
 ► Large randomised studies have associated 
prasugrel and ticagrelor with a reduction in 
ischaemic events versus clopidogrel in patients 
with acute coronary syndrome at long-term 
follow-up.
What does this study add?
 ► We found no significant differences in acute stent 
thrombosis between patients with ST-segment 
elevation myocardial infarction (STEMI) given 
prasugrel or ticagrelor versus clopidogrel.
How might this impact on clinical practice?
 ► Optimal antithrombotic strategies need to be 
developed to improve short-term outcome in 
patients with STEMI.
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also confirmed an observation from the HORIZONS-AMI 
trial12 of an increased risk of acute stent thrombosis of 
approximately 1% in absolute terms, which appeared 
confined to the 4 hours after the end of PCI.13
We aimed to investigate whether use of prasugrel or 
ticagrelor, versus clopidogrel, was associated with a reduc-
tion in the rate of acute stent thrombosis and whether 
either of the newer P2Y12 inhibitors improved 30-day 
clinical outcomes, in the overall trial population and as a 
function of treatment.
MeTHOds
design and participants
The EUROMAX trial enrolled patients who presented 
within 12 hours of symptom onset with a presumed diag-
nosis of STEMI and undergoing pPCI ( ClinicalTrials. gov 
registry, NCT01087723).11 The study complied with the 
Declaration of Helsinki. The protocol was approved by 
local ethics committees and health authorities. Patients 
provided written informed consent. 
Treatments
All patients received aspirin and an approved oral P2Y12 
inhibitor (clopidogrel, prasugrel, ticagrelor) as early as 
possible after first medical contact. Decisions regarding 
the choice of P2Y12 inhibitor, clopidogrel loading dose 
(300 or 600 mg) and other procedural options were left 
to physician preferences and local practices. Patients were 
randomised to bivalirudin or UFH/low-molecular-weight 
heparin with or without a glycoprotein IIb/IIIa inhibitor 
(per investigator usual practice and guidelines).
Patients in the bivalirudin arm received a bolus of 
0.75 mg/kg followed by an infusion of 1.75 mg/kg/
hour. The protocol specified that the infusion could be 
continued for ≥4 hours after PCI at a dose of 0.25 mg/kg/
hour; however, continuation of the PCI dose (1.75 mg/
kg/hour) was permitted.
Outcomes
Patients were followed to 30 days. The primary end point of 
this analysis was the occurrence of acute stent thrombosis 
as a function of the P2Y12 inhibitor used for the loading 
dose (ie, ticagrelor or prasugrel vs clopidogrel). Acute 
stent thrombosis was defined according to the Academic 
Research Consortium (ARC) definition as a stent throm-
bosis occurring <24 hours after the index PCI.14 Multiple 
secondary outcomes were analysed at 30 days, all of which 
were end points of the EUROMAX trial.11
In the EUROMAX trial, the primary outcome was the 
composite of all-cause death or protocol major bleeding 
not related to coronary artery bypass graft (CABG) 
surgery at 30 days. The key secondary 30-day outcome 
was a composite of all-cause death, myocardial re-infarc-
tion or non-CABG major bleeding. Other prespecified 
secondary outcomes included major adverse cardiovas-
cular events (MACE; a composite of death, re-infarc-
tion, ischaemia-driven revascularisation or stroke), net 
adverse clinical events (NACE, a composite of MACE 
and non-CABG major bleeding), each of the compo-
nents of the primary and principle secondary outcomes, 
ischaemia-driven revascularisation, major and minor 
bleeding, and ARC-defined stent thrombosis.14
Protocol-defined major bleeding was defined as 
bleeding unrelated to CABG surgery that included intra-
cranial, retroperitoneal or intraocular bleeding; access-
site haemorrhage requiring radiological or surgical 
intervention; a reduction in the haemoglobin concentra-
tion of >4 g/dL (2.5 mmol/L) without an overt source of 
bleeding; a reduction in the haemoglobin concentration 
of 3 g/dL (1.8 mmol/L) with an overt source of bleeding; 
re-intervention for bleeding; or use of any blood-product 
transfusion. Access-site haematomas, which did not 
require surgical or radiological intervention, were not 
counted as major bleeds regardless of their size. Protocol 
minor bleeding was defined as all other non-CABG-re-
lated bleeding or transfusion events. Bleeding events 
were also classified according to the Thrombolysis In 
Myocardial Infarction (TIMI) criteria.15
statistical analysis
A prespecified comparison of outcomes as a function of 
oral P2Y12 inhibitor used (prasugrel or ticagrelor vs clopi-
dogrel) was performed. Analyses were performed in the 
intent-to-treat population. The χ2 test or Fisher’s exact 
test was used for comparisons of event rates. The log-rank 
test was used to compute the significance of time-to-
event data. Continuous variables are reported as medians 
(IQRs). The Wilcoxon rank-sum test was used to compare 
continuous variables. A p value of <0.05 was considered 
significant. Categorical variables are reported as frequen-
cies and percentages. Rates of acute stent thrombosis 
were examined as a function of the P2Y12 inhibitor used 
for loading, and 30-day outcomes were examined as a 
function of the P2Y12 inhibitor used for maintenance 
therapy. To account for differences in baseline charac-
teristics in this postrandomisation subgroup analysis, a 
logistic regression analysis was performed. Variables in the 
logistic regression model included age >65 years, female 
sex, anaemia, hypertension, hyperlipidaemia, diabetes, 
smoking, creatinine clearance ≤60 mL/min, prasugrel/
ticagrelor versus clopidogrel, history of myocardial 
infarction, previous CABG, previous PCI, Killip class ≥II, 
access site (femoral vs radial), pre-PCI TIMI flow 0 or 1, 
single-vessel disease, placement of a drug-eluting stent, 
and treatment with bivalirudin versus standard of care. 
Analyses were performed with the use of SAS software, 
V.9.2.
ResulTs
Population
Of the 2198 patients triaged to pPCI in the EUROMAX 
trial, 2104 (95.7%) received an oral P2Y12 inhibitor 
loading dose (90.9% received the loading dose before 
angiography). Clopidogrel was used for loading in 1069 
patients, prasugrel in 629 patients and ticagrelor in 406 
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patients. P2Y12 inhibitor maintenance therapy after the 
procedure was used in 1927 patients (87.7%). Eight of 
these received ticlopidine and were excluded, leaving a 
population of 1919 patients. Figure 1 details the numbers 
of patients with data who received loading and mainte-
nance doses for each drug.
Baseline characteristics
Patient and procedural characteristics according to P2Y12 
inhibitor loading are shown in table 1. Patients given 
clopidogrel for the loading dose were older, more likely 
to be female, to have a history of myocardial infarction 
and to have had a failed procedure. In contrast, they 
were less likely to present with congestive heart failure 
and to have the procedure done by the radial approach. 
The type of P2Y12 inhibitor used for the loading dose was 
highly dependent on the country in which the patient was 
randomised. Patients who had a clopidogrel loading dose 
were more likely than those on prasugrel or ticagrelor to 
receive it before the angiogram was performed. Median 
delays between loading dose and angiogram were 50 min 
(IQR 35 to 66) in the overall population, 48 min (IQR 30 
to 65) in patients who received newer P2Y12 inhibitors as 
loading dose and 51 min (IQR 38 to 67) in patients who 
received clopidogrel as loading dose.
Patients on clopidogrel maintenance therapy showed 
features indicative of higher cardiovascular risk, with 
an older age, higher prevalence of major risk factors 
and history of myocardial infarction, higher Killip class 
and kidney dysfunction (see supplementary table S1). 
In addition, the rate of pre-PCI TIMI 3 flow was lower 
for patients receiving clopidogrel; they also had PCI less 
frequently performed and more frequently had a proce-
dural failure.
Acute stent thrombosis according to loading P2Y12 inhibitor
The rate of acute stent thrombosis did not differ according 
to the P2Y12 used for the loading dose: eight patients 
(0.8%) with prasugrel or ticagrelor versus five patients 
(0.5%) with clopidogrel (p=0.37). One additional case of 
stent thrombosis was excluded from the analysis due to 
missing data on the loading dose. After adjustment, no 
difference was observed (adjusted OR 0.50, 95% CI 0.13 
to 1.85, p=0.30, figure 2).
Thirty-day outcomes according to P2Y12 used for maintenance 
dose
There was no association between the type of P2Y12 inhib-
itor used for the maintenance dose and rates of the 30-day 
endpoints (table 2). The rate of death was lower (1.3% vs 
2.7%; p=0.03), and minor bleeds were higher in patients 
on prasugrel or ticagrelor (table 2). The rate of stent 
thrombosis was similar across subsets defined according 
to type of P2Y12 inhibitor.
After adjustment, there was no significant difference 
in clinical outcomes between groups except for lower 
rates of protocol major bleeding (p=0.029) and minor 
bleeding (p=0.025), as well as TIMI minor bleeding 
(p=0.0002) with clopidogrel (figure 2).
effect of P2Y12 type according to treatment arm (bivalirudin vs 
heparin with optional glycoprotein IIb/IIIa)
Information on the loading and maintenance P2Y12 
inhibitors used in the bivalirudin and heparin (with 
optional glycoprotein IIb/IIIa inhibitor) treatment arms 
is detailed in supplementary table S2.
Overall, the benefits of bivalirudin over heparin 
with optional glycoprotein IIb/IIIa inhibitor treat-
ment were consistent across subgroups defined by 
the use of prasugrel/ticagrelor or clopidogrel, with 
no statistical interaction between these subgroups 
(table 2). In particular, the interaction for acute stent 
thrombosis according to loading dose was not signif-
icant (p=0.74).
dIsCussIOn
In this prespecified analysis from the EUROMAX trial, we 
observed that use of the newer oral P2Y12 inhibitors, prasu-
grel or ticagrelor, was not associated with a lower rate of 
acute stent thrombosis or 30-day ischaemic outcomes as 
compared with the use of clopidogrel.
Rapid and potent platelet inhibition is key in order to 
reduce the risk of ischaemic complications in patients 
with STEMI. As a consequence, current guidelines recom-
mend the early use of P2Y12 inhibitors.
16 17 However, 
whereas the European Society of Cardiology guidelines16 
recommend using prasugrel or ticagrelor over clopido-
grel, the American College of Cardiology/American 
Heart Association guidelines17 stipulate the same level of 
recommendation for all three.
The absence of a difference in the rate of acute stent 
thrombosis according to the oral P2Y12 inhibitor used 
for the loading dose in our analysis is consistent with 
the existing literature. In the PLATO trial, the rate of 
acute stent thrombosis was not significantly different in 
patients on ticagrelor versus those on clopidogrel.5 In 
the ATLANTIC trial, prehospital administration of tica-
grelor did not improve pre-PCI coronary reperfusion. 
However, the rates of definite stent thrombosis were 
lower in the prehospital group, which can be interpreted 
as indicating that earlier administration may counteract 
a delayed onset of action of this agent in patients with 
Figure 1 Flow chart. The numerical differences between 
loading and maintenance dose totals are due to missing 
data.
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STEMI18 as the action of P2Y12 inhibitors is delayed due to 
a slower gastrointestinal absorption compared with that 
in healthy controls.7–10 This delay may be due to several 
factors, including the action of morphine or morphine 
derivatives, which are frequently used prehospital or 
intrahospital to relieve pain in patients with STEMI10 18 19 
and haemodynamic dysfunction in patients with shock or 
preshock.20
Table 1 Patient and procedural characteristics according to loading P2Y12 inhibitor
Characteristics Prasugrel or ticagrelor, n=1035 Clopidogrel, n=1069 p Value
Age, years 60.0±12.1 63.1±13.3 <0.0001
Women 222 (21.4) 272 (25.4) 0.031
Diabetes 142 (13.7) 136 (12.7) 0.50
Current smoker (within past 30 days) 439 (42.5) 466 (43.6) 0.009
Hypertension 434 (42.0) 470 (44.0) 0.36
Previous myocardial infarction 75 (7.3) 105 (9.8) 0.035
Previous PTCA/PCI 87 (8.4) 102 (9.5) 0.37
Previous CABG 18 (1.7) 26 (2.4) 0.27
Hyperlipidaemia* 424 (41.0) 337 (31.5) <0.0001
Country <0.0001
  France 554 (53.5) 233 (21.8)
  Netherlands 251 (24.3) 507 (47.4)
  Germany 120 (11.6) 93 (8.7)
  Denmark 85 (8.2) 61 (5.7)
  Other† 25 (2.4) 175 (16.4)
Killip class 0.11
  I 851/921 (92.4) 929/986 (94.2)
  II to IV 70/921 (7.6) 57/986 (5.8)
Creatinine clearance <0.0001
  ≤60 mL/min 123/924 (13.3) 168/991 (17.0)
  >60 mL/min 801/924 (86.7) 823/991 (83.0)
Anaemia 106/918 (11.5) 151/971 (15.6) 0.011
P2Y12 loading dose before angiography 882/1012 (87.2) 953/1007 (94.6) <0.0001
Pre-PCI TIMI 3 flow 207/923 (22.4) 178/899 (19.8) 0.020
PCI performed 928/1035 (89.7) 918/1069 (85.9) 0.0081
Radial access 608/1027 (59.2) 396/1037 (38.2) <0.0001
Thrombectomy 308/928 (33.2) 291/918 (31.7) 0.49
Post-PCI TIMI 3 flow 884/923 (95.8) 844/898 (94.0) 0.35
Procedural complication 57/928 (6.1) 66/918 (7.2) 0.37
Failed procedure 10/928 (1.1) 24/918 (2.6) 0.014
Anticoagulant used 0.043
  Unfractionated heparin 444/1048 (42.4) 526/1079 (48.7)
  Low-molecular-weight heparin 73/1048 (7.0) 20/1079 (1.9)
  Bivalirudin 531/1048 (50.6) 533/1079 (49.4)
Glycoprotein IIb/IIIa inhibitor use 431/1035 (41.6) 431/1069 (40.3) 0.54
  Bailout 119/431 (27.6) 79/431 (18.3)
  Routine 312/431 (72.4) 352/431 (81.7)
Data are presented as n (%), n/N (%) or mean±SD.
*Diagnosis of hyperlipidaemia or use of a lipid-lowering therapy.
†Austria, Czech Republic, Italy, Poland, Slovenia.
CABG, coronary artery bypass graft; PCI, percutaneous coronary intervention; PTCA, percutaneous transluminal coronary angioplasty; TIMI, 
Thrombolysis In Myocardial Infarction.
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Figure 2 Adjusted* ORs for outcomes by maintenance P2Y12 treatment. *Adjusted for age>65 years, anaemia, bivalirudin 
versus heparin±glycoprotein IIb/IIIa inhibitor, new P2Y12 maintenance dose, creatinine clearance ≤60 vs >60 mL/min, current 
smoker, diabetes, drug-eluting stent, female sex, femoral versus radial access, hyperlipidaemia, hypertension, Killip class≥II, 
preprocedural TIMI flow 0/1 vs 2/3, history of coronary artery bypass graft, previous percutaneous coronary intervention, 
previous MI, single-vessel disease. MACE, major adverse cardiac events (death or myocardial infarction, ischaemia-driven 
revascularisation or stroke); MI, myocardial infarction; NACE, net adverse clinical events (death or myocardial infarction, 
ischaemia-driven revascularisation, stroke or bleeding); TIMI, Thrombolysis In Myocardial Infarction.
Table 2 Unadjusted outcomes by P2Y12 inhibitor
Outcome Prasugrel or ticagrelor n=1135 Clopidogrel n=784 p Value
Interaction
p Value*
Acute stent thrombosis (≤24 hour)† 8/1035 (0.8) 5/1069 (0.5) 0.37‡ 0.74
30-day outcomes§
Death or major bleeding 63 (5.6) 47 (6.0) 0.68 0.47
Death, reinfarction or major bleeding 77 (6.8) 56 (7.1) 0.76 0.74
Death 15 (1.3) 21 (2.7) 0.03 0.69
  Cardiac death 14 (1.2) 18 (2.3) 0.07 0.87
Protocol bleeding
  Major 53 (4.7) 30 (3.8) 0.37 0.90
  Minor 88 (7.8) 43 (5.5) 0.05 0.93
  Major or minor 141 (12.4) 73 (9.3) 0.03 0.88
TIMI bleeding
  Major 19 (1.7) 15 (1.9) 0.70 0.97
  Minor 122 (10.7) 56 (7.1) 0.007 0.93
Reinfarction 15 (1.3) 11 (1.4) 0.88 0.39
Stent thrombosis (definite) 13 (1.1) 8 (1.0) 0.80 0.11
  Subacute (>24 hours to 30 days) 4 (0.4) 5 (0.6) 0.50‡ 0.33
MACE§ 44 (3.9) 43 (5.5) 0.10 0.86
NACE§ 90 (7.9) 66 (8.4) 0.70 0.82
Data are presented as n (%) or n/N (%).
*Interaction p value for the interaction between choice of P2Y12 inhibitor and effect of bivalirudin versus heparin.
†According to P2Y12 loading dose.
‡p Value calculated using Fisher’s exact test. All other p values calculated using the χ2 test.
§According to P2Y12 maintenance dose.
MACE, major adverse cardiovascular events (death, reinfarction, ischaemia-driven revascularisation or stroke); NACE, net adverse clinical 
events (death, reinfarction, ischaemia-driven revascularisation, stroke or major bleeding); TIMI, Thrombolysis In Myocardial Infarction.
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The lack of a difference in 30-day outcomes according 
to the P2Y12 inhibitor used as maintenance treatment 
in our study appears somewhat at variance with the 
results of the TRITON and PLATO trials, both of which 
demonstrated a significant reduction in the rate of isch-
aemic events in the overall population as well as in the 
group with STEMI.1 2 However, the present analysis is 
underpowered since EUROMAX was much a smaller 
trial than TRITON or PLATO, and we analysed 30 day 
rather than 1-year outcomes.
As detailed in figure 1, a substantial proportion of 
patients had a switch of P2Y12 inhibitor between loading 
and maintenance doses. This is probably because the 
loading dose was administered in a prehospital setting 
for most patients, while the maintenance dose was 
given in hospital. Hospital and prehospital antiplatelet 
protocols might differ as they are usually managed by 
different teams. This might be a confounding factor 
when analysing 30-day outcomes.
The use of bivalirudin for pPCI has been associ-
ated with an increase in the risk of acute stent throm-
bosis.11 12 In the HEAT-PPCI trial, despite the fact that 
newer oral P2Y12 inhibitors were used in >90% of cases, 
an increase in both early stent thrombosis and other 
ischaemic events was observed.21 Those results are 
consistent with our observations. The mechanism of 
bivalirudin-associated acute stent thrombosis is prob-
ably associated with a rapid clearance of the drug after 
discontinuation of the drug, resulting in an insuffi-
cient thrombin inhibition in the first hours following 
stent implantation and prior to the effectiveness of 
oral antiplatelet agents. Therefore, there is a ‘gap’ in 
antithrombotic protection.8 9 22 Whether this risk could 
be addressed by an intravenous antiplatelet agent with 
faster onset of action, for example, cangrelor, remains 
to be demonstrated.23–25 In contrast, several analyses 
tend to demonstrate that potent post-PCI thrombin 
inhibition decreases the risk of acute stent thrombosis. 
In the BRIGHT trial,26 in a subgroup analysis from 
EUROMAX27 and in an exploratory analysis of the 
MATRIX trial,28patients who received a prolonged infu-
sion of bivalirudin at the full dose of 1.75 mg/kg/hour 
after PCI had no excess risk of acute stent thrombosis.
limitations
These data were derived from a prespecified analysis 
of postrandomisation data. Thus, the decision to use 
clopidogrel or one of the newer P2Y12 inhibitors was left 
to the discretion of the investigators and confounding 
cannot be excluded. In addition, there were major 
differences in the geographical distribution and the 
baseline clinical characteristics as a function of the agent 
used, some of which can affect the risk of ischaemic or 
bleeding complications. Even if we performed multi-
variable adjustments, our results may be partially due 
to residual confounding. The low number of events 
and the large CI observed in the comparison of stent 
thrombosis between the two groups makes a statistical 
type 2 error possible. This result should therefore be 
interpreted with caution. The fact that most patients 
received pretreatment with P2Y12 inhibitors might have 
attenuated differences in platelet inhibition between 
the two groups. However, precise information on the 
timing of the administration of the loading dose is 
not available. The relatively low numbers of patients 
receiving each of the two newer P2Y12 agents and low 
number of stent thromboses prevent a sound compar-
ison between prasugrel and ticagrelor. This comparison 
is currently being done in a randomised trial (ISAR-
REACT 5 trial NCT01944800). Finally, EUROMAX was 
an open-label trial. However, a central adjudication 
committee blinded to treatment allocation reviewed all 
events.
COnClusIOns
The rate of acute stent thrombosis did not differ between 
patients who received a loading dose of prasugrel or tica-
grelor and those who received clopidogrel. Following 
adjustment, 30-day outcomes were similar between 
patients receiving prasugrel or ticagrelor and those 
receiving clopidogrel for the maintenance dose, with the 
exception of an increased risk of bleeding events with the 
newer agents. These results were consistent regardless of 
the anticoagulation strategy used.
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